Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CATALYST PHARMACEUTICALS, INC.

(CPRX)
  Report
Delayed Nasdaq  -  04:00:01 2023-03-21 pm EDT
16.53 USD   +0.79%
03/16Economic Data, Credit Suisse Financing in Focus as Exchange-Traded Funds, Equity Futures Mixed Pre-Bell
MT
03/16Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2023
CI
03/16Transcript : Catalyst Pharmaceuticals, Inc., Q4 2022 Earnings Call, Mar 16, 2023
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Catalyst Pharmaceuticals, Inc: Optimistic scenario

03/06/2023 | 11:44am EDT

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company. It is focused on in-licensing, developing and commercializing new drugs for patients with rare diseases. This small biotech has an interesting history and significant potential for the coming years.


ę MarketScreener.com 2023
Stocks mentioned in the article
ChangeLast1st jan.
CATALYST PHARMACEUTICALS, INC. 0.79% 16.53 Delayed Quote.-11.13%
ELI LILLY AND COMPANY -0.76% 331.08 Delayed Quote.-9.50%
JOHNSON & JOHNSON 0.00% 153.89 Delayed Quote.-12.88%
All news about CATALYST PHARMACEUTICALS, INC.
03/16Economic Data, Credit Suisse Financing in Focus as Exchange-Traded Funds, Equity Future..
MT
03/16Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2023
CI
03/16Transcript : Catalyst Pharmaceuticals, Inc., Q4 2022 Earnings Call, Mar 16, 2..
CI
03/15Catalyst Pharmaceuticals' Q4 Non-GAAP EPS, Revenue Advance; Guidance Issued
MT
03/15Catalyst Pharmaceuticals, Inc. : Other Events, Financial Statements and Exhibits (form 8-K..
AQ
03/15Catalyst Pharmaceuticals, Inc. Plans Are Underway to Seek Approval from the FDA to Incr..
CI
03/15Earnings Flash (CPRX) CATALYST PHARMACEUTICALS Posts Q4 EPS $0.31, vs. Street Est of $0..
MT
03/15Earnings Flash (CPRX) CATALYST PHARMACEUTICALS Reports Q4 Revenue $61M, vs. Street Est ..
MT
03/15Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results an..
GL
03/15Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results an..
GL
More news
Analyst Recommendations on CATALYST PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2023 382 M - -
Net income 2023 171 M - -
Net cash 2023 325 M - -
P/E ratio 2023 10,9x
Yield 2023 -
Capitalization 1 746 M 1 746 M -
EV / Sales 2023 3,72x
EV / Sales 2024 2,80x
Nbr of Employees 82
Free-Float 92,4%
Upcoming event on CATALYST PHARMACEUTICALS, INC.
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 16,53 $
Average target price 21,65 $
Spread / Average Target 31,0%
EPS Revisions
Managers and Directors
Patrick J. McEnany Chairman, President & Chief Executive Officer
Alicia Grande CFO, Treasurer, Principal Accounting Officer & VP
Steven R. Miller Chief Operating & Scientific Officer
Gary Ingenito Chief Medical & Regulatory Officer
Brian Elsbernd Chief Legal & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
CATALYST PHARMACEUTICALS, INC.-11.13%1 733
JOHNSON & JOHNSON-12.88%402 206
NOVO NORDISK A/S5.43%320 277
ELI LILLY AND COMPANY-8.81%300 873
ABBVIE INC.-3.40%275 418
MERCK & CO., INC.-4.60%268 710